From Our Thought Leaders

GENESIS Pharma Expands Alnylam Partnership into Nordic Region to Broaden Access to RNAi Therapies

The expanded partnership adds Denmark, Finland, Norway and Sweden to GENESIS Pharma’s existing network of thirteen Southeast European markets. It grants rights for the commercialization of Alnylam’s RNAi therapeutics for serious ca... Read more

12 June, 2026 | Friday | News
Anocca Doses First Patients with KRAS-Targeted TCR-T Therapy in Pancreatic Cancer Trial

Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, announced the successful dosing of the first patients across multiple clinical sites with ANOC-001, a ... Read more

12 June, 2026 | Friday | News
Thermo Fisher Launches Chronic Hand Eczema Registry to Advance Real-World Evidence Generation

New registry will generate robust real-world evidence on disease burden, treatment patterns and long-term effectiveness of newly approved and emerging therapies  Thermo Fisher Scientific, the world leader in serving science, announced the lau... Read more

12 June, 2026 | Friday | News
Axplora Consolidates Global UDCA Manufacturing in India to Strengthen Integrated API Supply Network

Move reinforces Axplora’s integrated API supply model, expands critical manufacturing capabilities in India and  enables Farmabios to sharpen focus on Steroids and HPAPI leadership   Axplora, a global leader in the manufacturi... Read more

12 June, 2026 | Friday | News
T-CURX Secures First Clinical Trial Approval for TCX-001, Advancing Novel Non-Viral CAR-T Therapy into the Clinic

Clinical Trial approval for TCX-001 is another significant development milestone for T-CURX and marks the transition of T-CURX from a pre-clinical to a clinical-stage biotech company TCX-001 targeting Siglec-6 is a first-in-class autologous, non... Read more

12 June, 2026 | Friday | News

Bio Finance

Idorsia Secures CHF 250 Million Financing Facility to Strengthen Balance Sheet and Extend Cash Runway

Senior secured term loan of up to CHF 250 million with a 5‑year maturity at a fixed 7% interest rate First tranche will fully refinance the existing New Money Facility, maturing in May 2027 Eliminates near‑term debt maturities and strengthens b... Read more

10 June, 2026 | Wednesday | News
Philips CEO Roy Jakobs Highlights Strong Q1 2026 Performance with Sales Growth, Margin Expansion and Robust Order Intake

  Q1 2026 Group performance Comparable order intake growth 6% Group sales of EUR 3.9 billion, reflecting 4% increase in comparable sales Income from operations increased to EUR 241 million Adjusted EBITA margin increased 40 basis points t... Read more

07 May, 2026 | Thursday | Company results

Contract Services

Mabion and Oddifact Partner to Advance MabionCD20 for Rare Disease Applications

  Mabion S.A., a Polish biotechnology company, has signed a letter of intent (LoI) with French TechDev company Oddifact SAS to evaluate and advance MabionCD20 for potential use in rare diseases, marking the reactivation of the Company’s... Read more

18 June, 2026 | Thursday | News
Catalent Launches Qai, Enterprise AI Platform to Advance Quality Management Across Global Manufacturing Network

Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the launch of Qai, an enterprise AI tool designed to elevate the best quality... Read more

18 June, 2026 | Thursday | News

BioPharma Video

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close